1-Methyl-D-Tryptophan in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery

• Status: Completed
• Trial end date: 2012-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This phase I trial is studying the side effects and best dose of 1-methyl-D-tryptophan in treating patients with metastatic or refractory solid tumors that cannot be removed by surgery. Biological therapies, such as 1-methyl-D-tryptophan, may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by stimulating the immune system.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Tryptophan

Criteria

Inclusion Criteria:

• Histologically confirmed solid malignancy that is metastatic or unresectable and for which standard effective antineoplastic therapy does not exist or is no longer effective

• Patients are eligible for enrollment into the trial regardless of the types of previous therapies administered

• Patients with known brain metastases will only be eligible after their tumors have been treated with definitive resection and/or radiotherapy and they are neurologically stable for at least 1 month off steroids

• No known untreated brain metastases

• ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100%

• Life expectancy > 4 months

• WBC ≥ 3,000/μL

• ANC ≥ 1,500/μL

• Platelet count ≥ 100,000/μL

• Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

• AST and ALT ≤ 2.5 times ULN

• Creatinine normal OR creatinine clearance ≥ 60 mL/min

• No history of gastrointestinal disease causing malabsorption or obstruction, including, but not limited to, any of the following:

• Crohn's disease

• Celiac sprue

• Tropical sprue

• Bacterial overgrowth/blind-loop syndrome

• Strictures

• Adhesions

• Achalasia

• Bowel obstruction

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective double-method contraception during and for at least 1 month after completion of study treatment

• No history of allergic reactions (significant urticaria, angioedema, anaphylaxis) attributed to compounds of similar chemical or biologic composition to 1-methyl-d-tryptophan (including L-tryptophan or 5-hydroxy-tryptophan supplements)

• No active autoimmune disease (i.e., psoriasis, extensive atopic dermatitis, asthma, inflammatory bowel disorder, multiple sclerosis, uveitis, vasculitis), chronic inflammatory condition, or any condition requiring concurrent use of any systemic immunosuppressants or steroids for any reason

• Mild-intermittent asthma requiring only occasional beta-agonist inhaler use or mild localized eczema allowed

• No uncontrolled concurrent illness including, but not limited to, any of the following:

• Ongoing or active infection

• Symptomatic congestive heart failure

• Unstable angina pectoris

• Myocardial infarction or percutaneous coronary interventions within the past 6 months

• Cardiac arrhythmia

• Active autoimmune diseases

• Major psychiatric illness or social situation that would limit compliance with study requirements as judged by the primary investigator at each site

• Patients with well-controlled, chronic medical conditions under the supervision of the patient's primary physician (i.e., hypertension, hyperlipidemia, coronary heart disease, diabetes mellitus) are eligible

• No HIV-positive patients or patients with other acquired/inherited immunodeficiencies

• No other active malignancy

• No concurrent immunosuppressants, including steroids

• Recovered from all prior therapy

• No prior gastric bypass surgery

• No prior extensive small bowel resection

• No prior experimental active immunotherapy consisting of targeted monoclonal antibodies or pharmaceutical compounds

• Commercially available active immunotherapy (e.g., adjuvant interferon) must have completed therapy over 1 year prior to enrollment and have no evidence of autoimmune sequelae

• Prior therapy with approved monoclonal antibodies (e.g., bevacizumab, cetuximab, panitumumab, or trastuzumab) allowed

• At least 4 weeks since prior and no other concurrent investigational agents

• More than 4 weeks since prior chemotherapy or radiotherapy (6 weeks for nitrosoureas or mitomycin C)

• No concurrent supplements containing L-tryptophan or derivatives

• No patients with an allo-transplant of any kind (including those with a xenograft heart valve)

• No other concurrent commercial agents or therapies